BookR: School of Health Core Facilities Booking
PubMed Publications| Keyword search (4,163 papers available) |  |
"Li Z" Authored Publications:
| Title | Authors | PubMed ID | |
|---|---|---|---|
| 1 | Management of brain-heart multimorbidity: a clinical practice guideline | Edwards JD; Li Z; McFarlane P; Rabi DM; Gilbert J; Bajaj HS; MacIntosh BJ; Bittman J; Feldman RD; Dresser G; Terenzi K; Swartz R; Gabor J; Pearson GJ; Selby P; Wharton S; Warburton DER; Pakhalé S; Styra R; Baker B; Tu K; Hawkins M; Stone JA; Vaillancourt T; Poon S; Virani SA; Jain R; Jones PH; Sandhu RK; Ganesh A; Andrade JG; Stern S; Habert J; Rivard L; Roumeliotis P; Udell JA; Campbell T; Bacon SL; Trudeau L; Keshavjee K; Pham T; Cheng G; Lewis KB; Maar M; Stacey D; Oldenburg B; Dhukai AR; Pasricha SV; Sh | 41912243 HKAP |
| 2 | Laboratory-scale simulation study on the bioremediation of marine oil pollution by phosphate-solubilizing bacteria Bacillus subtilis PSB-1 | Du Z; Li Z; Chen X; Liu M; Feng L; Li Q; Chen Z; Chen Q; | 41707285 ENCS |
| 3 | Understanding the environmental fate and risks of organophosphate esters: Challenges in linking precursors, parent compounds, and derivatives | Li Z; Chen R; Xing C; Zhong G; Zhang X; Jones KC; Zhu Y; | 40845576 CHEMBIOCHEM |
| 4 | Disentangled representation learning for multi-view clustering via von Mises-Fisher hyperspherical embedding | Li Z; Luo Z; Bouguila N; Su W; Fan W; | 40664160 ENCS |
| 5 | Enhanced biodegradation of crude oil by phosphate-solubilizing bacteria Bacillus subtilis PSB-1: Overcoming soluble phosphorus deficiency | Wang X; Du Z; Li Z; Liu M; Mu J; Feng L; Chen Z; Chen Q; | 40609441 ENCS |
| 6 | Lung fibrosis: drug screening and disease biomarker identification with a lung slice culture model and subtracted cDNA Library | Guo T; Lok KY; Yu C; Li Z; | 25290944 JMSB |
| 7 | Effects of electron acceptors and donors on anaerobic biodegradation of PAHs in marine sediments | Chen Q; Li Z; Chen Y; Liu M; Yang Q; Zhu B; Mu J; Feng L; Chen Z; | 38113802 ENCS |
| 8 | Degradation of enrofloxacin by a novel Fe-N-C@ZnO material in freshwater and seawater: Performance and mechanism | Geng C; Chen Q; Li Z; Liu M; Chen Z; Tao H; Yang Q; Zhu B; Feng L; | 37619630 ENCS |
| 9 | Health behavior profiles in young survivors of childhood cancer: Findings from the St. Jude Lifetime Cohort Study | Webster RT; Dhaduk R; Gordon ML; Partin RE; Kunin-Batson AS; Brinkman TM; Willard VW; Allen JM; Alberts NM; Lanctot JQ; Ehrhardt MJ; Li Z; Hudson MM; Robison LL; Ness KK; | 36943740 PSYCHOLOGY |
| 10 | Lymph Node Metastases Detection Using Gd2O3@PCD as Novel Multifunctional Contrast Imaging Agent in Metabolic Magnetic Resonance Molecular Imaging | Rasouli Z; Riyahi-Alam N; Khoobi M; Haghgoo S; Gholibegloo E; Ebrahimpour A; H A; Hashemi H; | 36304774 PERFORM |
| 11 | Indoor exposure to selected flame retardants and quantifying importance of environmental, human behavioral and physiological parameters | Li Z; Zhang X; Wang B; Shen G; Zhang Q; Zhu Y; | 35461943 CHEMBIOCHEM |
| 12 | Modeling of Flame Retardants in Typical Urban Indoor Environments in China during 2010-2030: Influence of Policy and Decoration and Implications for Human Exposure | Li Z; Zhu Y; Wang D; Zhang X; Jones KC; Ma J; Wang P; Yang R; Li Y; Pei Z; Zhang Q; Jiang G; | 34410710 CHEMBIOCHEM |
| 13 | Self-tunable engineered yeast probiotics for the treatment of inflammatory bowel disease | Scott BM; Gutiérrez-Vázquez C; Sanmarco LM; da Silva Pereira JA; Li Z; Plasencia A; Hewson P; Cox LM; O' Brien M; Chen SK; Moraes-Vieira PM; Chang BSW; Peisajovich SG; Quintana FJ; | 34183837 CHEMBIOCHEM |
| 14 | Change in Pain Status and Subsequent Opioid and Marijuana Use Among Long-Term Adult Survivors of Childhood Cancer. | Huang IC, Alberts NM, Buckley MG, Li Z, Ehrhardt MJ, Brinkman TM, Allen J, Krull KR, Klosky JL, Greene WL, Srivastava DK, Robison LL, Hudson MM, Anghelescu DL | 33409451 PSYCHOLOGY |
| Title: | Self-tunable engineered yeast probiotics for the treatment of inflammatory bowel disease | ||||
| Authors: | Scott BM, Gutiérrez-Vázquez C, Sanmarco LM, da Silva Pereira JA, Li Z, Plasencia A, Hewson P, Cox LM, O' Brien M, Chen SK, Moraes-Vieira PM, Chang BSW, Peisajovich SG, Quintana FJ | ||||
| Link: | https://pubmed.ncbi.nlm.nih.gov/34183837/ | ||||
| DOI: | 10.1038/s41591-021-01390-x | ||||
| Publication: | Nature medicine | ||||
| Keywords: | |||||
| PMID: | 34183837 | Category: | Date Added: | 2021-06-29 | |
| Dept Affiliation: |
CHEMBIOCHEM
1 Department of Cell and Systems Biology, University of Toronto, Toronto, Ontario, Canada. 2 Biosystems and Biomaterials Division, National Institute of Standards and Technology, Gaithersburg, MD, USA. 3 Department of Chemistry and Biochemistry, University of Maryland, College Park, MD, USA. 4 Concordia University, Montreal, Quebec, Canada. 5 Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 6 Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology; Experimental Medicine Research Cluster (EMRC), and Obesity and Comorbidities Research Center (OCRC), University of Campinas, Campinas, Brazil. 7 Department of Ecology and Evolutionary Biology, University of Toronto, Toronto, Ontario, Canada. 8 Centre for the Analysis of Genome Evolution and Function, University of Tor |
||||
Description: |
Inflammatory bowel disease (IBD) is a complex chronic inflammatory disorder of the gastrointestinal tract. Extracellular adenosine triphosphate (eATP) produced by the commensal microbiota and host cells activates purinergic signaling, promoting intestinal inflammation and pathology. Based on the role of eATP in intestinal inflammation, we developed yeast-based engineered probiotics that express a human P2Y2 purinergic receptor with up to a 1,000-fold increase in eATP sensitivity. We linked the activation of this engineered P2Y2 receptor to the secretion of the ATP-degrading enzyme apyrase, thus creating engineered yeast probiotics capable of sensing a pro-inflammatory molecule and generating a proportional self-regulated response aimed at its neutralization. These self-tunable yeast probiotics suppressed intestinal inflammation in mouse models of IBD, reducing intestinal fibrosis and dysbiosis with an efficacy similar to or higher than that of standard-of-care therapies usually associated with notable adverse events. By combining directed evolution and synthetic gene circuits, we developed a unique self-modulatory platform for the treatment of IBD and potentially other inflammation-driven pathologies. |
